finance.yahoo.comOCT 201 min read$LFMD

LifeMD to Report Third Quarter 2026 Financial Results on November 9

LifeMD (LFMD) will release Q3 2026 financial results on November 9, 2026, before market open, followed by a conference call at 8:30 a.m. ET. The company provides virtual primary care and pharmacy services.

Original reporting

finance.yahoo.com

Published Oct 20, 2026, 8:05 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 21, 2026, 12:33 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

LifeMD to Report Third Quarter 2026 Financial Results on November 9 — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$LFMDNeutralLow

Why it matters

The filing is a standard earnings‑date announcement with no new financial metrics, offering limited trading impetus.

Market read

A routine earnings‑date notice; minimal immediate market impact.

What to watch

Potential regulatory changes or partnership announcements that could be disclosed in the upcoming earnings.

Relevance 4/10Novelty 3/10Timing: pre‑market on Nov 9

Background

LifeMD (Nasdaq: LFMD) provides virtual primary care and pharmacy services across the U.S.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$LFMDNeutralMedium confidence

Context

LifeMD announced it will report its Q3 2026 results on November 9 before market open.

Expected impact

possible slight pressure as traders price in upcoming earnings uncertainty

Evidence & confidence

No financial numbers are disclosed; the news is a routine earnings‑date notice, offering limited actionable insight.

Market effects

Sector

None significant; virtual‑care sector may see modest attention ahead of the report.

Regional

U.S. market only, limited broader impact.

Global

Low

Counterpoint

What could challenge this read

Investors could ignore the date and focus on longer‑term growth trends in telehealth rather than short‑term positioning.

Key entities

Company
LifeMD, Inc.
Virtual primary‑care and pharmacy provider.

Read at source ← All news

SEP 20

$LFMDMed

LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?

LifeMD (LFMD) partnered with AT&T to offer free virtual-health memberships to 29 million eligible customers in 11 states, with a nationwide expansion planned for 2027. The $19 monthly fee is waived, but services like visits and prescriptions remain payable. LifeMD aims to convert access into recurring demand for paid care, potentially reducing acquisition costs and benefiting from repeat consultations. The phased rollout allows for measuring enrollment and utilization before expansion.

yahoo.com2 min

SEP 16

$TMed

AT&T Waives $19 LifeMD Fee for 100 Million Wireless and Fiber Customers

AT&T is partnering with LifeMD to waive its $19 monthly membership fee for over 100 million wireless and fiber customers, making it the first carrier to bundle no-cost virtual healthcare access. The rollout begins in 11 states, with the rest following in January 2027. LifeMD (LFMD) provides telehealth services, and AT&T aims to enhance customer retention. AT&T's stock is valued at $29.03 per share, with projected slight earnings declines due to heavy capital spending.

kobaran.com3 min

AUG 13

$LFMDMedAI 9/10

LifeMD (LFMD) Q2 2026 Earnings Call Transcript

LifeMD (LFMD) reported Q2 2026 revenue of $47.3M, within guidance ($47M-$50M) but down 4% YoY, and an adjusted EBITDA loss of about $3.5M. Full-year revenue guidance was cut to $205.5M-$212.5M and adjusted EBITDA to negative $6M to breakeven. Active subscribers were 356,000. Cash was $25.1M.

fool.com6 min

AUG 10

$LFMDHighAI 9/10

LifeMD Q2 2026 Earnings: Revenue Misses $49.16M Estimate

LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3M, below the $49.16M consensus estimate, with GAAP EPS loss of $0.16 versus a $0.01 EPS expectation. The company posted an adjusted EBITDA loss and cut full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven adjusted EBITDA. LFMD shares fell after the release.

sci-tech-today.com4 min

AUG 5

$LFMDMed

LifeMD Reports Second Quarter 2026 Results

LifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results ● Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. ● Approximately

SEC EDGAR 8-K6 min

OCT 22

$TSLAHighAI 8/10

Tesla’s Q3 profit falls 43% as operating costs rise

Tesla's Q3 2026 net income fell 43% YoY to $787M, with EPS declining 44%. Revenue remained flat at $28B, but operating expenses rose 39%. Automotive revenue decreased 3%, while energy revenue dropped 16%. Gross profit increased 9%. Tesla plans to focus on cost reduction and factory utilization.

finance.yahoo.com2 min